Ahead 300
Overview
The Ahead 300, later commercialized as BrainScope One, is a portable, non-invasive, non-radiation emitting, point-of-care medical device designed to aid clinicians in the rapid and objective assessment of traumatic brain injury (TBI), including concussions and brain bleeds. It utilizes proprietary, patent-protected electroencephalography (EEG) capabilities, advanced signal processing, sophisticated algorithms, and machine learning to analyze head-injured patient data. The device provides a multi-modal assessment, offering a comprehensive panel of data to assist in the diagnosis of the full spectrum of TBI. It is intended for use as an adjunct to standard clinical practice to aid in the evaluation of patients being considered for a head CT, who sustained a closed head injury within 72 hours, present with a Glasgow Coma Scale (GCS) score of 13-15, and are between the ages of 18-85 years. The Ahead 300 helps identify patients likely to have structural brain injury visible on a CT scan and can potentially reduce the number of unnecessary head CT scans in emergency departments.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered EEG analysis for TBI assessment
- Identifies structural brain injuries (brain bleeds)
- Assesses functional brain injuries (concussions)
- Portable, handheld device with disposable electrode headset
- Non-invasive and non-radiation emitting
- Provides rapid, objective assessment at point of care
- Reduces unnecessary head CT scans
- Integrates advanced signal processing and machine learning
- Offers a multi-modal, comprehensive panel of data
- Actionable results downloadable to PDF
Use Cases
- Emergency Departments for TBI evaluation
- Urgent Care Centers for head injury assessment
- Concussion Clinics for objective diagnosis
- Military healthcare system for battlefield TBI assessment
- Sports medicine settings for concussion management
What Physicians Need to Know
The Ahead 300 is an adjunct to standard clinical practice and should not be used as a substitute for a CT scan. Clinical judgment should always be used when interpreting the device's outputs, and it should not be used as a stand-alone diagnostic device. It is intended for use in patients aged 18-85 with a Glasgow Coma Scale (GCS) score of 13-15 who have sustained a closed head injury within 72 hours and are being considered for a head CT. The device can help identify patients who are likely to have a structural brain injury visible on a CT scan, or those who may need further evaluation or observation. It also provides an objective marker of brain function impairment (Brain Function Index) and a Concussion Index to aid in evaluating concussion and tracking recovery.
The Ahead 300 utilizes a proprietary disposable electrode headset that connects to a handheld display device, which uses smartphone technology. BrainScope's AI solution can also be applied to EEG captured by third-party devices. Software updates for the BrainScope device are performed by BrainScope personnel.
Details
| Category | Neurology AI, Triage & ER/ICU AI |
| Pricing | Contact for pricing |
| Deployment | Cloud |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Emergency Medicine, Neurology, Sports Medicine |
FDA clearance history
This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.
| Decision date | Number | Name as listed by FDA |
| 2016-09-22 | K161068 510(k) | Ahead 300 |
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Ahead 300
Videos
Product demos, reviews, and walkthroughs for Ahead 300.







